DSS’s current revenue remains minuscule versus Astral’s size.
Management sees revenue potential of ₹500 crore over five years. Since DSS operates in high-value specialty chemical niches, it is expected to sustain a 20-25% Ebitda margin, which is significantly above traditional commodity chemical businesses, the management said. Ebitda is short for earnings before interest, taxes, depreciation, and amortization.
